This protocol addresses Linear IgA bullous dermatosis (LIAD) in the specific clinical context of drug-induced disease (DILAD), where a pharmacological agent is identified as the precipitating cause.
Drug-induced linear IgA dermatosis is a recognised presentation of Linear IgA bullous dermatosis in which a specific medication is implicated as the trigger. Recognition of the offending agent and the ability to act on it are central to the management approach in this setting.
Management in DILAD centres on addressing the causative pharmacological trigger. The complete structured regimen — including the specific intervention and any additional guidance — is available via the full protocol below.